India’s Glenmark Puts Off U.S. Acquisitions Due To Financial Crisis
This article was originally published in PharmAsia News
Because of the global financial crisis, India's Glenmark Pharmaceuticals has put off plans to acquire U.S. companies at least for another year. Glenn Saldanha, managing director, told an analyst the company had to reconsider its merger-and-acquisition plans because of the economic situation, but expects to meet its net profit forecasts for the next two years, on track for $210 million next year and $282 million in the 2010 fiscal year. He said Glenmark would resume considering U.S. acquisitions in a year to 18 months. (Click here for more
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.